TORTS — Failure To Warn

In re Fosamax (Alendronate Sodium)

New Jersey Law Journal

   | 0 Comments

Because there is clear evidence that the FDA would not have approved a stronger warning to the precautions section of the Fosamax label prior to plaintiff's fracture, plaintiffs' failure-to-warn action is pre-empted.

This premium content is reserved for New Jersey Law Journal subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202610572260

Thank you!

This article's comments will be reviewed.